Targeting a specific receptor to reduce cancer spread and treatment failure
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
This study is looking at how a specific receptor in the body might help slow down the spread of aggressive breast cancer, especially Triple Negative Breast Cancer, and aims to find new ways to improve treatments and prevent the cancer from coming back, which could be really helpful for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11036295 on NIH RePORTER |
What this research studies
This research investigates how targeting the Oncostatin M receptor can help suppress the spread of aggressive breast cancer, particularly Triple Negative Breast Cancer (TNBC). It focuses on understanding the role of this receptor in cancer cell differentiation and the immune response within the tumor microenvironment. By exploring the interactions between cancer cells and immune cells, the research aims to identify new therapeutic strategies that could enhance treatment effectiveness and prevent recurrence. Patients may benefit from insights that could lead to improved therapies for managing their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic Triple Negative Breast Cancer who are experiencing treatment failure.
Not a fit: Patients with non-aggressive forms of breast cancer or those who are not diagnosed with Triple Negative Breast Cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce metastasis and improve outcomes for patients with aggressive breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, suggesting potential for success in this approach.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Jackson, Mark W. — Case Western Reserve University
- Study coordinator: Jackson, Mark W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.